Wuxi Beta Pharmatech Secures Strategic Investment from Three-Tier Government-Backed Funds Ahead of IPO

VCBeat News has learned that Wuxi Beita Pharmatech Co., Ltd. recently completed a RMB 10 million strategic investment round, with Jiangyin New Guolian Group—the largest state-owned investment platform in Jiangyin—increasing its capital stake. This marks the third time a government-backed investment fund from Wuxi has invested in Beita Pharmatech’s equity, following earlier participations by Xichuangtou (controlled by the State-owned Assets Supervision and Administration Commission of Wuxi) and Jiangyin Binjiang Chengyuan Investment Group (controlled by the Administrative Committee of Jiangyin High-Tech Industrial Development Zone) in 2021.

Previously, Wuxi Beita Pharmatech Co., Ltd. completed a tens-of-millions-yuan Series B financing round led by Oriental Fortune Capital Holding Co., Ltd. The proceeds from this investment are primarily intended to support the industrialization of future carbon-14 (C-14) radiopharmaceuticals, as well as the development of new C-14 technologies and products. The participation of government-backed funds underscores recognition of Beita Pharmatech’s focused commitment to deepening its expertise in nuclear technology applications (isotopes) and building a comprehensive C-14 industry chain. It also reflects confidence in the company’s future growth potential, aiming to accelerate its advancement within the biopharmaceutical sector.

Wuxi Beita Pharmatech Co., Ltd. is the first enterprise in China specializing in the development and application of nuclear technologies for strategic Carbon-14 (C14) isotopes, established with support from Wuxi’s Leading Overseas Returnee Entrepreneurship Program. The company’s core business includes the development of C14 source materials, preparation of key C14-labeled precursor compounds, provision of C14 labeling technical services, production of C14-labeled drugs and labeled products, and the localization of tracer technologies. In recent years, Beita Pharmatech has labeled nearly 200 small-molecule new drug candidates for more than 80 domestic listed companies, industry leaders, and research institutes, thereby breaking the previous reliance on overseas C14 labeling services. This achievement has been widely acclaimed and has significantly accelerated the development of innovative pharmaceuticals and agrochemicals in China.

Since 2010, Wuxi Beita Pharmatech Co., Ltd. has collaborated with nuclear reactor institutions, including the Nuclear Power Institute of China, to develop Carbon-14 (C14) source materials. The company has overcome technical challenges in target material preparation, separation, and purification, achieving the domestic production of C14 source materials for the first time. Supported by the Ministry of Science and Technology’s Innovation Fund, the Jiangsu Provincial Science and Technology Support Program, the Changsha Municipal Science and Technology Plan, and the Jiangyin Municipal Science and Technology Innovation Special Project, the company has realized the domestic production of nearly 100 key C14-labeled precursor compounds, laying a solid foundation for the development of C14 technology in China. In 2015, the company established the Robert Grubbs Nobel Laureate Isotope Labeling Research Institute and the Academician Zhou Yongmao Workstation, cultivating a young team specializing in C14 isotope labeling technology and creating more than 30 patented technologies with independent intellectual property rights, centered on TEFLON pipeline systems.

C-14 is primarily used for radioactive isotope labeling and tracing, representing a significant aspect of the peaceful utilization of nuclear energy. It also constitutes a vital contribution by the nuclear industry to the pharmaceutical, pesticide, and environmental protection sectors, as well as to the national economy and public welfare. As a radioactive isotope with strategic application value, C-14 functions akin to a navigation and positioning system in the microscopic realm, enabling researchers to elevate observational and investigative capabilities to the cellular, subcellular, and even molecular levels. Currently, C-14 labeled products are mainly employed for tracing purposes in fields such as innovative drug development, pesticide research, biotechnology, and medical diagnostics, owing to their unparalleled detection sensitivity and unique, irreplaceable utility.

Jiangyin Xinguolian Investment Development Co., Ltd. was established in March 2001 as a wholly state-owned enterprise funded by the Jiangyin Municipal People's Government, with a registered capital of RMB 700 million. Relying on three core sectors—energy and environmental protection, asset management, and financial investment—Jiangyin Xinguolian Group has implemented its strategic layout. The group owns multiple subsidiaries, including Jiangyin Power Investment Company, Jiangyin Xinguolian Power Development Co., Ltd., Jiangyin Jinyang Financing Guarantee Co., Ltd., Jiangyin Xinlian Financing Guarantee Co., Ltd., Jiangyin Market Construction Co., Ltd., and Jiangyin Textile Market Co., Ltd., making it the largest operational state-owned assets enterprise in Jiangyin.